William Vaughn McCall1, Ruth M Benca2, Peter B Rosenquist3, Mary Anne Riley3, Chelsea Hodges3, Brittany Gubosh3, Laryssa McCloud3, Jill C Newman4, Doug Case4, Meredith Rumble2, Mark Mayo5, Kaitlin Hanley White2, Marjorie Phillips6, Andrew D Krystal5. 1. Department of Psychiatry and Health Behavior, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA wmccall@gru.edu. 2. Department of Psychiatry, The University of Wisconsin-Madison, Madison, WI, USA. 3. Department of Psychiatry and Health Behavior, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA. 4. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA. 5. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA. 6. The Pharmacy Department, Georgia Regents Medical Center, Augusta, GA, USA.
Abstract
BACKGROUND/AIMS: Suicide is a major public health concern, yet there are very few randomized clinical trials that have been conducted to reduce suicidal ideation in patients at risk of suicide. We describe the rationale and refinements of such a trial that is designed to assess the effect of a hypnotic medication on suicidal ideation in adult outpatients currently experiencing suicidal ideation. METHODS: "Reducing Suicidal Ideation Through Insomnia Treatment" is a multi-site randomized clinical trial that includes three recruiting sites and one data management site. This 4-year study is in its second year of recruitment. The purpose of the study is to compare hypnotic medication versus placebo as an add-on treatment to a selective serotonin reuptake inhibitor as a means of reducing suicidal ideation in depressed adult outpatients with insomnia and suicidal ideation. The safety features of the study follow the 2001 National Institutes of Health guidelines for studies that include patients at risk of suicide. RESULTS: In total, 584 potential participants have undergone telephone screening; 67% of these failed the phone screen, most often due to an absence of expressed suicidal ideation (26% of the telephone screen fails). A total of 115 people appeared for a face-to-face baseline assessment, and 40 of these had completed a taper off of their ineffective psychotropic medications before the baseline assessments. In all, 64% of those who completed baseline assessments failed to proceed to randomization, most commonly because of no clinically significant suicidal ideation (51% of those excluded at baseline). One participant was offered and accepted voluntary psychiatric hospitalization in lieu of study participation. Thus far, 40 participants have been randomized into the study and 88.7% of scheduled visits have been attended, with 93.8% adherence to the selective serotonin reuptake inhibitor and 91.6% adherence to the randomizedhypnotic versus placebo. None of the randomized participants have required hospitalization or had a suicide attempt. CONCLUSION: By carefully considering the inclusion and exclusion criteria and other safety features, the safe conduct of randomized clinical trials in suicidal adult patients is possible, including the inclusion of participants who have undergone a prescribed tapering off of psychotropic medications prior to baseline assessment.
RCT Entities:
BACKGROUND/AIMS: Suicide is a major public health concern, yet there are very few randomized clinical trials that have been conducted to reduce suicidal ideation in patients at risk of suicide. We describe the rationale and refinements of such a trial that is designed to assess the effect of a hypnotic medication on suicidal ideation in adult outpatients currently experiencing suicidal ideation. METHODS: "Reducing Suicidal Ideation Through Insomnia Treatment" is a multi-site randomized clinical trial that includes three recruiting sites and one data management site. This 4-year study is in its second year of recruitment. The purpose of the study is to compare hypnotic medication versus placebo as an add-on treatment to a selective serotonin reuptake inhibitor as a means of reducing suicidal ideation in depressed adult outpatients with insomnia and suicidal ideation. The safety features of the study follow the 2001 National Institutes of Health guidelines for studies that include patients at risk of suicide. RESULTS: In total, 584 potential participants have undergone telephone screening; 67% of these failed the phone screen, most often due to an absence of expressed suicidal ideation (26% of the telephone screen fails). A total of 115 people appeared for a face-to-face baseline assessment, and 40 of these had completed a taper off of their ineffective psychotropic medications before the baseline assessments. In all, 64% of those who completed baseline assessments failed to proceed to randomization, most commonly because of no clinically significant suicidal ideation (51% of those excluded at baseline). One participant was offered and accepted voluntary psychiatric hospitalization in lieu of study participation. Thus far, 40 participants have been randomized into the study and 88.7% of scheduled visits have been attended, with 93.8% adherence to the selective serotonin reuptake inhibitor and 91.6% adherence to the randomized hypnotic versus placebo. None of the randomized participants have required hospitalization or had a suicide attempt. CONCLUSION: By carefully considering the inclusion and exclusion criteria and other safety features, the safe conduct of randomized clinical trials in suicidal adult patients is possible, including the inclusion of participants who have undergone a prescribed tapering off of psychotropic medications prior to baseline assessment.
Authors: A A Nierenberg; B R Keefe; V C Leslie; J E Alpert; J A Pava; J J Worthington; J F Rosenbaum; M Fava Journal: J Clin Psychiatry Date: 1999-04 Impact factor: 4.384
Authors: Ana S Iltis; Sahana Misra; Laura B Dunn; Gregory K Brown; Amy Campbell; Sarah A Earll; Anne Glowinski; Whitney B Hadley; Ronald Pies; James M Dubois Journal: JAMA Psychiatry Date: 2013-12 Impact factor: 21.596
Authors: Michael F Grunebaum; Steven P Ellis; Naihua Duan; Ainsley K Burke; Maria A Oquendo; J John Mann Journal: Neuropsychopharmacology Date: 2011-10-12 Impact factor: 7.853
Authors: William V McCall; Ruth M Benca; Meredith E Rumble; Doug Case; Peter B Rosenquist; Andrew D Krystal Journal: J Psychiatr Res Date: 2019-06-19 Impact factor: 4.791
Authors: William V McCall; Ruth M Benca; Peter B Rosenquist; Nagy A Youssef; Laryssa McCloud; Jill C Newman; Doug Case; Meredith E Rumble; Steven T Szabo; Marjorie Phillips; Andrew D Krystal Journal: Am J Psychiatry Date: 2019-09-20 Impact factor: 18.112
Authors: W Vaughn McCall; Ruth M Benca; Peter B Rosenquist; Mary Anne Riley; Laryssa McCloud; Jill C Newman; Doug Case; Meredith Rumble; Andrew D Krystal Journal: Am J Psychiatry Date: 2016-09-09 Impact factor: 18.112
Authors: Meredith E Rumble; William V McCall; Daniel A Dickson; Andrew D Krystal; Peter B Rosenquist; Ruth M Benca Journal: J Clin Sleep Med Date: 2020-08-15 Impact factor: 4.062